Confused about the new cholesterol guidelines? Here’s what to know

Confused about the new cholesterol guidelines? here’s what to know

Your cholesterol levels can affect your risk of heart disease and stroke. And the longer you have high cholesterol, the greater your risk.

That’s why leading medical groups recommend getting your cholesterol checked regularly, and working to lower your levels even when they’re only slightly elevated, in some cases. Last month, the American College of Cardiology and other medical organizations released new guidelines to help patients and doctors know what cholesterol levels to aim for, and which medications might help.

We asked doctors to break down the recommendations.

To start, know your levels.

The guidelines recommend that adults, starting at age 19, have their cholesterol checked at least every five years. (Before that, children should have their cholesterol checked once, between ages 9 to 11, to screen for inherited high cholesterol.)

A lipid panel, which you can have done with a blood draw at your primary care doctor’s office, looks at several types of cholesterol. Of these, doctors focus most on low-density lipoprotein, or LDL, a “bad cholesterol” that can build up in your artery walls. We have “overwhelming evidence” that the lower your LDL levels, the lower your risk of a cardiovascular event like a heart attack or a stroke, said Dr. Erin D. Michos, associate director of preventive cardiology at Johns Hopkins University School of Medicine.

The guidelines also recommend that all adults now have levels of Lipoprotein(a), a genetically determined form of cholesterol, tested at least once. Lp(a) increases the risk of heart disease, regardless of your other lipid levels. “It’s an amplifier of whatever your risk is,” said Dr. Ann Marie Navar, an associate professor of cardiology at the U.T. Southwestern Medical Center in Dallas. We reach our adult levels in childhood, and they remain relatively stable over a lifetime, with a few exceptions.

There’s another, less widely used test for a different lipoprotein called ApoB. This is perhaps the best measure of cholesterol related risk, Dr. Navar said, because it reflects the total number of “bad” cholesterol particles, including not just LDL, but also Lp(a) and another type called vLDL. This makes it a more reliable measure, especially for people with metabolic disease, including diabetes and cardiovascular-kidney-metabolic syndrome, because of differences in LDL particle size and density in these patients.

Determine your individual risk.

It’s never too early to talk with your doctor about your risk of heart disease, and you should build heart-healthy habits like eating a Mediterranean-style or DASH diet and exercising regularly as soon as possible. But starting at age 30, the conversation can include an actual prediction of your future risk. The guidelines use a new calculator, called PREVENT, that includes risk factors that weren’t previously taken into account, including body mass index and kidney disease.

It assesses both short-term (10-year) and long-term (30-year) risk.

Measuring long-term risk is particularly useful for people 30 to 59. Doctors might look at a younger patient who isn’t at risk of heart disease in the next 10 years, but could be in the long-term, and recommend that they start taking a statin.

“We want to reduce their lifetime exposure” to these bad cholesterol particles, Dr. Michos said. “The risk is not only how high a level is, it’s how many years one’s arteries are exposed to these high levels,” similar to how doctors look at “pack-years” of smoking.

People who are at low 10-year risk don’t typically need to start medication, unless they have an LDL level of 160 mg/dL or greater, or have a high 30-year risk.

For people who are at borderline or intermediate risk, a coronary arterial calcium (CAC) score — which uses a low-dose CT scan to look for evidence of plaque buildup in the heart arteries — can help with decision making. That evidence can be a powerful motivator for asymptomatic patients to take medication, said Dr. Martha Gulati, a professor of cardiology at Houston Methodist DeBakey Heart & Vascular Center.

In considering treatment, doctors also take into account other factors that might raise a person’s risk of heart disease, such as South Asian race, diabetes, early menopause, pre-eclampsia or gestational diabetes, for example. They also consider inflammatory conditions like rheumatoid arthritis and psoriasis, since inflammation contributes to plaque buildup in the arteries.

Know your goal.

The new guidelines give specific target levels of LDL based on short- and long-term risk of heart disease.

•For general prevention of heart disease in people who are at borderline or intermediate 10-year risk and don’t have diabetes or heart disease, the goal is an LDL level under 100 mg/dL.

•For patients at high 10-year risk, people with longstanding Type 2 diabetes or complications of diabetes, or people with CAC scores over 100, the goal is under 70 mg/dL.

•For most patients who have already had a heart attack or a stroke, the goal is under 55 mg/dL. This might seem like an especially aggressive goal. But “with very intensive cholesterol lowering, we can actually shrink plaque,” Dr. Michos said, reducing the risk of future cardiovascular issues.

Work with your doctor to find the right medication plan.

Most patients with continuously high cholesterol levels will need medication. Statins, which block the liver from making cholesterol, are still the first line of treatment. “They’re cheap,” Dr. Gulati said. “We’ve had them for over four decades. They reduce bad cardiovascular outcomes.”

“They’re good drugs despite their bad P.R.,” she added, referring to common concerns about side effects. She noted that in randomized controlled trials, people who took a placebo experienced the same side effects as those who took statins.

But there are also many other medications at doctors’ disposal, including ezetimibe, which inhibits the absorption of cholesterol from food; bempedoic acid, which blocks production of cholesterol in the liver; and a much newer class of drugs called PCSK9 inhibitors, which help the liver clear LDL from the blood. (The PCSK9 inhibitors are currently approved as injections, but trials for a pill form are also underway.)

“If you try a statin and can’t tolerate it, we have other medications,” Dr. Navar said. “If you try a statin but you’re not at goal, you may need more than one medication.”

“There are a lot of options out there,” she added.

  • Credits: The New York Times
  • Author: Nina Agrawal
  • Illustration: Andrei Cojocaru

Compartir:

Facebook
X
LinkedIn

Dos pepinos no está mal

Raúl Ruiz __________________________ Se fue el año de volada y cuando uno menos lo pensaba, se llegó la inauguración de la Copa Mundial de Fútbol, 2026. La justa deportiva arrastró no solamente el círculo deportivo nacional. Invadió también al sector político, social, artístico,  industrial. La ausencia presidencial en el estadio, causó sorpresa en pequeñas personalidades del momento. Como Lili Téllez y acompañamiento de siempre. Ah, y un séquito de cien gritones afuera del estadio que repetían ¡Fuera Morena! ¡fuera Morena!

Leer más »
Rezago energético: 1.3 millones de mexicanos sin acceso a electricidad Brinda MediChihuahua más de 160 mil atenciones a menores de 15 años durante el 2026 Inauguran oficialmente el Festival del Libro y las Artes en el Paseo Juan Gabriel How to remove apps you never use (or at least hide them) Defiende Sheinbaum logros del T-MEC tras las amenazas de Trump de no renovarlo La exposición de Claudia ante el Mundial - Carlos Angulo Parra Advierten por continuidad de lluvias, tormentas eléctricas y granizadas en sur del estado Listo operativo de Seguridad Vial afuera de Plaza de la Mexicanidad por Feria Juárez SpaceX sets milestone with world’s largest I.P.O., furthering Musk’s power Revés al abstencionismo en Coahuila; la participación ciudadana creció un 11% Nuevos Samsung Galaxy Buds4 Pro: una apuesta de audio más inteligente Video: México es un anfitrión de segunda en el Mundial 2026 | Jesús Silva-Herzog Márquez